TGEN Tecogen Inc

Targeted Genetics to Present at Euregenethy Third Annual International Conference SEATTLE, April 13 /PRNewswire-FirstCall/ -- Barrie J. Carter, Ph.D., chief scientific officer of Targeted Genetics Corporation , will speak at two events during the Euregenethy Third Annual International Conference on Thursday, April 15, 2004. Dr. Carter is an expert in the field of gene-based therapies, and has over 20 years of experience in the development of adeno-associated viral (AAV) vectors for commercial applications. Targeted Genetics is utilizing its AAV vector technology in three product development programs: tgAAVCF for the treatment of cystic fibrosis (CF), the most advanced CF gene therapy clinical program to date; tgAAC09 for the prevention of AIDS; and tgAAC94 for the treatment of rheumatoid arthritis (RA). Dr. Carter will give a presentation focused on the Company's RA clinical program, and the potential benefits of targeted gene delivery directly to affected joints of patients suffering from this disease. Dr. Carter also will participate in a press conference focused on clinical progress in the field of gene delivery. Event details are as follows: What: Euregenethy Forum - Press Conference Where: Langen, Germany When: Thursday, April 15, 2004 1:00 PM CEST What: Euregenethy Forum - Presentation Where: Langen, Germany When: Thursday, April 15, 2004 2:00 PM CEST Targeted Genetics Corporation develops gene-based products for preventing and treating acquired and inherited diseases. The Company has three clinical product development programs, targeting cystic fibrosis, AIDS prophylaxis and rheumatoid arthritis. The Company also has a promising pipeline of product candidates focused on hemophilia and cancer and a broad platform of gene delivery technologies, as well as a promising body of technology for cellular therapy under development by its subsidiary company, CellExSys. For more information about the Company, visit its website at http://www.targetedgenetics.com/. NOTE: This release contains forward-looking statements regarding our product pipeline and clinical trials. These statements involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Actual results could differ materially from expectations for a number of reasons, including our failure to make progress with our clinical trials, our failure to obtain positive results from our preclinical programs, our failure to obtain regulatory approval and the other risks describedin the section entitled "Factors Affecting Our Operating Results, Our Business and Our Stock Price" in our annual report on Form 10-K for the year ended December 31, 2003. You should not rely unduly on these forward-looking statements, which apply onlyas of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectations. DATASOURCE: Targeted Genetics Corporation CONTACT: Courtney Self of Targeted Genetics Corporation, +1-206-521-7392 Web site: http://www.targetedgenetics.com/

Copyright